Success Metrics

Completion Rate
0%(0/1)
Active Trials
0(0%)
Terminated
1(33%)

Phase Distribution

Ph phase_1
1
33%
Ph phase_2
2
67%

Phase Distribution

1

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution3 total trials
Phase 1Safety & dosage
1(33.3%)
Phase 2Efficacy & side effects
2(66.7%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 3 finished

Non-Completion Rate

100.0%

3 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Terminated(3)

Detailed Status

Withdrawn2
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
0.0%
Most Advanced
Phase 2

Trials by Phase

Phase 11 (33.3%)
Phase 22 (66.7%)

Trials by Status

terminated133%
withdrawn267%

Recent Activity

0 active trials
Showing 3 of 3
terminatedphase_2

Donor Regulatory T Cells Infusion in Patients With Chronic Graft-versus-host Disease (GVHD)

NCT01903473
withdrawnphase_1

Safety of T Regulatory Cell Therapy in Subjects With COVID-19 Induced Acute Respiratory Distress Syndrome

NCT04737161
withdrawnphase_2

Treg Cells for AGVHD in Non-myeloablative UCB Transplant

NCT02118311

Clinical Trials (3)

Showing 3 of 3 trials
NCT01903473Phase 2

Donor Regulatory T Cells Infusion in Patients With Chronic Graft-versus-host Disease (GVHD)

Terminated
NCT04737161Phase 1

Safety of T Regulatory Cell Therapy in Subjects With COVID-19 Induced Acute Respiratory Distress Syndrome

Withdrawn
NCT02118311Phase 2

Treg Cells for AGVHD in Non-myeloablative UCB Transplant

Withdrawn

All 3 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
3